Literature DB >> 2866529

The involvement of activated ras genes in determining the transformed phenotype.

C J Marshall, K Vousden, B Ozanne.   

Abstract

Activated ras oncogenes have been identified in a wide range of tumours. All examples of ras gene activation in tumours so far result from amino acid substitution at Gly12 or Gln61. To learn more about how mutations in ras genes lead to transformation, we have analysed transforming growth factor production in NIH/3T3 cells transformed by each of the three ras genes. These results show that the transformed phenotype of these cells results from a combination of the presence of the mutant ras protein and TGF alpha production. In a second series of experiments we have shown that the mutation of a ras gene in a tumour cell line can lead to tumour progression towards a more aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866529     DOI: 10.1098/rspb.1985.0084

Source DB:  PubMed          Journal:  Proc R Soc Lond B Biol Sci        ISSN: 0950-1193


  4 in total

1.  NIH-3T3 cells transformed with a ras oncogene exhibit a protein kinase C-mediated inhibition of agonist-stimulated Ca2+ inflow.

Authors:  A J Polverino; B P Hughes; G J Barritt
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

2.  Malignant transformation of murine fibroblasts by a human c-Ha-ras-1 oncogene does not require a functional epidermal growth factor receptor.

Authors:  I A McKay; P Malone; C J Marshall; A Hall
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

3.  Transformation and stimulation of DNA synthesis in NIH-3T3 cells are a titratable function of normal p21N-ras expression.

Authors:  I A McKay; C J Marshall; C Calés; A Hall
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

4.  Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.

Authors:  Jinyu Li; Raffaella Sordella; Scott Powers
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.